Lumipulse® G pTau 181
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Tau phosphorylated at threonine 181 (pTau 181) in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
The CSF biomarker supports the probability of AD pathology only as an adjunct to other diagnostic evaluations.
Product number 230350
Product number 230367
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Citations
- Documentation
- Insights
- FAQ
- Product inquiry
- Related products
-
Details
See the LUMIPULSE G1200 working in this video:
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Citations
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all product documentation right away.
Other documents
FileWhitepaper - Biomarkers for Alzheimers disease.pdf (pdf, 148.72 kb)FileFileFilePractical guide for lumbar puncture.pdf (pdf, 263.94 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Feb 20, 2024Publication - Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients
We would like to draw your attention to a first publication on our Lumipulse® G NfL solution. In this article you will find a method comparison of CSF...
Dec 1, 2023CTAD 2023 – Spotlight on recent advances in blood-based biomarkers for Alzheimer’s disease
Both fluid and imaging biomarkers provide biological evidence for the underlying etiology of cognitive impairment. The core fluid biomarkers of...
Jul 10, 2023 -
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Product inquiry
-
Related products